# Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

> **NCT00630630** · PHASE4 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 3 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Levetiracetam
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00630630
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630630, "Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00630630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*